The buyback is a capital return signal but non-binding; actual execution depends on market conditions and liquidity. Monitor the pace of repurchases in upcoming 10-Qs and whether the CCO departure leads to any commercial strategy changes.
ALNY drugs
ALNY drug pipeline →- ● brezosiran 3/10 Phase 1b
- ● GIVLAARI 3/10 Approved (FDA approval 2019-11-20)
- ● ONPATTRO 3/10 Approved (marketed); Phase 3 (APOLLO-B) completed
- ● OXLUMO 3/10 Approved
- ● ALN-6222 2/10 unknown (no registered ClinicalTrials.gov record found; appears to be an early, minimally disclosed pipeline program)
- 2 more · All ALNY drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 5 $156.66entry
- T+1 · 11d ago −0.46%α −0.77% · $155.94
- T+5 · 5d ago −0.01%α −3.30% · $156.65
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alnylam announced the departure of Chief Commercialization Officer Tolga Tanguler in December 2026 and authorized a $1.0 billion share repurchase program, with $500 million expected by year-end 2026. The buyback signals capital return confidence, while the CCO departure is a routine executive change with no replacement named.
Key Facts
- Tolga Tanguler, EVP and Chief Commercialization Officer, will depart in December 2026; no replacement named.
- Board authorized a $1.0 billion share repurchase program on November 2, 2026.
- Company anticipates repurchasing approximately $500 million by end of 2026 and the balance during 2027.
- Repurchase program has no expiration date and may be modified, suspended or discontinued at any time.
Financial Impact
$1.0 billion buyback authorization, representing approximately 4.7% of $21.4B market cap; $500M expected by end of 2026.
Risk Factors
- Buyback may be modified, suspended or discontinued without notice; no obligation to repurchase any specific amount.
- CCO departure without a named successor could create temporary leadership gap in commercialization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001178670-26-000080 |
| Document: 0001178670-26-000080-index-headers.html | 0001178670-26-000080 |
| Document: 0001178670-26-000080-index.html | 0001178670-26-000080 |
| Document: 0001178670-26-000080.txt | 0001178670-26-000080 |
Track record
15 reports on ALNY
1 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +26.35% at T+5 after the Oct 23, 2026 report. 1 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $160.53 Now $159.73 −0.50% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $165.50 Now $159.73 −3.49% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $165.04 Now $159.73 −3.22% settles Nov 20
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $165.04 Now $159.73 −3.22% settles Nov 20
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $156.66 to $156.65 Now $159.73 +1.96% ▼ −0.01% −3.30% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Viewing Entry $156.66 to $156.65 Now $159.73 +1.96% ▼ −0.01% −3.30% vs SPY
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $165.00 to $155.94 Now $159.73 −3.19% ▼ −5.49% −2.79% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $174.00 to $156.66 Now $159.73 −8.20% ▼ −9.97% −5.24% vs SPY
- Oct 23, 202624d ago Institutional Cluster Bearish 4/10 Entry $224.03 to $165.00 Now $159.73 +28.70% ▲ +26.35% +25.79% vs SPY
- Aug 17, 202613w ago Court Ruling Neutral 4/10 Entry $228.61 to $240.08 Now $159.73 −30.13% ▲ +5.02% +5.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers